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Abstract
Supported by several epidemiological studies and a large number of animal studies, certain 
polyfluorinated alkyl acids are believed to be immunotoxic, affecting particularly humoral 
immunity. Our aim was to investigate the relationship between the antibody response following 
vaccination with an inactivated trivalent influenza vaccine and circulating levels of 
Perfluorooctanoate (PFOA) and perfluorooctanesulfonate (PFOS). The study population consisted 
of 411 adults living in the mid-Ohio region of Ohio and West Virginia where public drinking 
water had been inadvertently contaminated with PFOA. They participated in a larger cross-
sectional study in 2005/2006 and were followed up in 2010, by which time serum levels of PFOA 
had been substantially reduced but were still well above those found in the general population. 
Hemagglutination inhibition tests were conducted on serum samples collected preinfluenza 
vaccination and 21 ± 3 days postvaccination in 2010. Serum samples were also analyzed for 
PFOA and PFOS concentrations (median: 31.5 and 9.2 ng/ml, respectively). Questionnaires were 
conducted regarding the occurrence and frequency of recent (during the last 12 months) 
respiratory infections. Our findings indicated that elevated PFOA serum concentrations are 
associated with reduced antibody titer rise, particularly to A/H3N2 influenza virus, and an 
increased risk of not attaining the antibody threshold considered to offer long-term protection. 
Although the direct relationship between weakened antibody response and clinical risk of 
influenza is not clear, we did not find evidence for an association between self-reported colds or 
influenza and PFOA levels nor between PFOS serum concentrations and any of the endpoints 
examined.
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Polyfluorinated alkyl acids (PFAAs) are organofluorine compounds used in various 
manufacturing processes that are readily found in the environment. Perfluorooctanoate 
(PFOA or C8) and perfluorooctanesulfonate (PFOS) are two of the most common PFAAs. 
They have long half-lives, initially reported to be 3.5 years (Olsen et al., 2007), and their 
persistence in the blood of animals and humans has been linked to a number of adverse 
health outcomes (Steenland et al., 2010). There is evidence of widespread exposure to 
PFOA and PFOS in the general population although levels vary between countries and over 
time (Calafat et al., 2007; Fromme et al., 2007; Kannan et al., 2004; Kato et al., 2011b; 
Olsen et al., 2012). In 2007–2008, the mean serum concentrations in the general population 
of the United States were 13.2 ng/ml (PFOS) and 4.1 ng/ml (PFOA) (Kato et al., 2011b). 
Although mean serum concentrations of PFOA and PFOS have decreased in recent years in 
developed countries (Glynn et al., 2012; Kato et al., 2011b; Schroter-Kermani et al., 2012), 
likely due to decreased production and use of PFOS and PFOA, the stability of the 
compounds and recent increases in serum PFOA concentrations observed in Korea and 
PFAAs in China (Harada et al., 2010; Jin et al., 2007), along with their potential human 
health effects, are of concern.
The Dupont Company in West Virginia had used PFOA and related substances in 
manufacturing processes since 1951. PFOA contamination of water supplies downwind and 
downstream of the Dupont plant, located near the Ohio River, has been observed since the 
1980s. Although production has been drastically reduced and manufacturing processes have 
been changed, investigations of possible health outcomes related to this contamination 
continue. In 2001, a class action lawsuit was filed by residents from affected communities 
alleging health effects from the contaminated water supplies. As part of a class action 
settlement, the C8 Health Project was established to investigate possible health effects in 
exposed populations, and follow-up studies in a subgroup of this population were conducted 
in 2009–2010.
Animal and human studies have suggested PFAAs are immunotoxic, affecting particularly 
humoral immunity. For example, in laboratory rodent studies, exposure to either PFOS or 
PFOA, even at blood concentrations similar to those detected in highly exposed humans, 
suppressed antibody responses (DeWitt et al., 2008, 2012; Fair et al., 2011; Yang et al., 
2002). Using human leukocytes, in vitro exposure to PFOA inhibited interleukin (IL)-4 and 
IL-10, cytokines which help regulate immune responses (Corsini et al., 2011; Fletcher et al., 
2011). Grandjean et al. (2012) found that increased PFOA or PFOS serum concentrations 
were associated with reduced antibody responses to childhood diphtheria and tetanus 
vaccines. Similarly, a small Norwegian study recently reported a negative association 
between maternal PFOA and PFOS serum concentrations and rubella vaccine response, as 
well as an increase in certain infections in children (Granum et al., 2013).
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One of the most commonly used vaccines in the developed world is the seasonal influenza 
vaccine. Influenza is a viral illness with the potential for serious morbidity and mortality, 
particularly in children and the elderly, resulting in more than 30 000 fatalities per year in 
the United States alone (Blanciforti, 2006). The CDC currently recommends universal 
influenza vaccination for all individuals older than 6 months who do not have specific 
contraindications (eg, severe egg allergy, history of Guillain-Barré) (NCIRD, 2011). In the 
United Kingdom, vaccination is recommended for those in specific high-risk groups 
(Department of Health, 2011). Factors associated with a reduced antibody response to 
influenza vaccination include older age (Goodwin et al., 2006; Goronzy et al., 2001; 
Murasko et al., 2002; Weksler and Szabo, 2000; Wick and Grubeck-Loebenstein, 1997), 
smoking status (Cruijf, 1999), use of immunosuppressive therapies, and chronic 
inflammatory illnesses (Admon et al., 1997; Blumberg et al., 1998; Cullen et al., 2012; 
Dengler et al., 1998; Holvast et al., 2009; Robertson et al., 2000; Salles et al., 2010; Tiu et 
al., 2011; Vilchez et al., 2002). Chronic stress has also been found to be negatively 
associated with vaccine antibody titers in both young and old (Pedersen et al., 2009; 
Vedhara et al., 1999).
In contrast to childhood vaccines, for which pre-existing immunity is typically low, 
prevaccination antibody levels to influenza can be highly variable in adults due to previous 
infections or vaccinations with cross-reacting epitopes. For this reason, measurement of both 
pre- and postvaccination antibody levels is important to establish an individual's response to 
a vaccine. This study offered a unique opportunity to assess the immune response to 
influenza vaccine in a group of residents who lived in the 6 contaminated water districts 
surrounding the Dupont chemical plant.
Materials and Methods
Study Design
This study was conducted in 2010/2011 as part of the C8 Science Panel Studies and was 
approved by the appropriate Institutional Review Board (IRB) and comply with all relevant 
national, state, and local regulations. The C8 Health Project initially collected data on 69 
030 eligible subjects between August 2005 and August 2006. Eligible participants were 
those who had consumed water for at least 1 year between 1950 and December 3, 2004, 
while living, working, or going to school in one of the following 6 water districts: Little 
Hocking Water Association of Ohio; City of Belpre, Ohio; Tupper Plains–Chester District of 
Ohio; Village of Pomeroy, Ohio; Lubeck Public Service District of West Virginia; Mason 
County Public Service District of West Virginia; or private water sources within 
aforementioned districts and areas of documented PFOA contamination. Details of the study 
enrollment process, including consenting procedures, have been described elsewhere 
(Frisbee et al., 2009). In 2010, 755 participants were recalled and invited to participate in a 
second interview and provide a second blood sample for PFAA analysis (Fitz-Simon et al., 
2013). This interview included questions regarding the occurrence and frequency of a 
number of recent (during the last 12 months) common infections, including coughs, colds, 
flu, and other upper respiratory infections. Frequency information was only gathered for 
cold episodes but not influenza specifically. A subset of these participants who had not yet 
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received the annual flu vaccine were offered the vaccine and asked to consent to pre- and 
postvaccination blood sampling to determine virus-specific antibody titers.
The study was conducted with every participant receiving an influenza vaccine and short 
health questionnaire. The prevaccination serum sample was collected at the time of 
vaccination, and the postvaccination sample was collected 21 ± 3 days later (FDA, 2007). 
Subjects (411) were healthy adults aged over 18 years who did not have a history of 
influenza vaccination in the past 3 months or a relatively high risk of influenza 
complications (cancer, recent history of influenza, and vaccine allergy).
Vaccine
A single lot of FLUVIRIN (Novartis, Cambridge, Massachusetts), an inactivated trivalent 
vaccine containing influenza serotypes A/H3N2 and A/H1N1 (swine flu) and influenza B, 
was used in the study.
Hemagglutination Inhibition Assays
Sera were tested for influenza-specific antibody by a hemagglutination inhibition (HI) assay 
using turkey red blood cells (tRBCs) for A/H3N2 and A/H1N1 and influenza B. Nonspecific 
HI activity was removed by treating the serum samples with receptor destroying enzyme 
(RDE, ATCC) overnight at 4°C. The RDE-treated sera were tested for residual HI activity 
by adding 50 μl of the treated serum to 50 μl of the 0.5% tRBCs. This mixture was incubated 
for 30–60 min and then read to determine whether HI activity was present. If HI activity was 
present, the nonspecific agglutination inhibitors were removed by adsorption of the serum 
with packed tRBCs for 1 h at 4°C. Patient serum was prepared by using a 2-fold dilution 
curve starting at 1:10 and ending at 1:10 240. The serum dilution series (25 μl/dilution) was 
mixed with 25 μl of optimized dilutions of the 3 influenza antigens in a V-bottom 96-well 
plate and incubated for 45–60 min at 25°C. Fifty microliters of standardized 0.5% tRBCs 
were then added to the appropriate wells and incubated at room temperature for 30–60 min 
to allow the RBCs to settle to the bottom of the well. Positive (known titer of influenza-
specific antibodies) and negative (no influenza-specific antibodies) control sera were run in 
parallel to the test subject sera. Quality control plates were prepared to confirm the 
optimized antigen. If there were no hemagglutinins present in the sample, as in the control 
wells that did not contain antigen, the tRBC pellet would stream across the bottom of the 
well forming a distinct “teardrop” shape. The plates were read when the “teardrop” in the 
control wells (no antigen) extended from the middle of the well to the outer edge of the well. 
If influenza-specific antibody was present in the serum sample, the influenza antigen would 
be bound by the antibody before it could interact with the tRBCs to cause agglutination. The 
dilution of serum at which a complete “teardrop” formed was designated at the influenza-
specific antibody titer for the antigen being tested.
PFOA and PFOS Concentrations
Laboratory measurement of PFOA and PFOS used online solid phase extraction coupled 
with reversed-phase high-performance liquid chromatography separation and detection by 
isotope-dilution tandem mass spectrometry (Kato et al., 2011a). The detection limits were 
0.5 ng/ml (PFOA) and 0.2 ng/ml (PFOS). At the laboratory, interday precision, calculated as 
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the relative standard deviation of 60 repeated measurements in a 6-month period, was below 
8% (PFOA: 7.6% [3.1 ng/ml] and 5.8% [11.7 ng/ml]; PFOS: 7.3% [8.2 ng/ml] and 7.6% 
[27.5 ng/ml]). Intraday precision, calculated as the relative standard deviation of 5 repeated 
measurements within 1 day, ranged from approximately 2% to 6% (PFOA: 2.8% [3.1 ng/ml] 
and 1.7% [11.7 ng/ml]; PFOS: 5.8% [8.2 ng/ml] and 4.9% [27.5 ng/ml]).
Analysis
Vaccine response measures—The geometric mean antibody titer (GMT) rises for 
different participant characteristics are described. Statistical significance between participant 
groups for GMTs was determined by examining the bounds of the 2-sided 95% confidence 
intervals to determine whether they overlapped. To explore the associations between 
antibody titers and PFOA and PFOS levels, several measures of vaccine response were used. 
Firstly, the antibody titer rise following vaccination was calculated by subtracting the 
prevaccination titer from the postvaccination titer. Secondly, the ratio of pre- and 
postvaccination titers was examined by dividing the postvaccine titer by the prevaccine titer. 
The antibody titer rise and ratio for antibodies specific for each strain showed skewed 
distributions and were log10 transformed for the analysis.
Additional analyses used dichotomous surrogate outcomes to measure vaccine response. The 
associations between PFOA/PFOS and seroconversion, defined as a 4-fold or greater 
increase in antibody titer following vaccination, and seroprotection, defined as a 
postvaccination HI titer > 1:40 (irrespective of prevaccination levels) were examined. The 
seroprotection threshold is usually considered indicative of protection from a clinical testing 
perspective (Beyer et al., 2004).
Exposure measures—Concentrations of PFOA and PFOS showed skewed distribution 
and were log10 transformed. PFOA and PFOS were examined as linear variables in both the 
transformed and untransformed form and grouped as categorical exposure groups of 
quartiles of PFOA and PFOS levels.
Regression analysis—The associations between the antibody titer rise or ratio and 
untransformed, log10 transformed and concentration quartiles of PFOA and PFOS were 
examined using linear regression. Given the significant skew in the PFOA measurements, 
only log10-transformed and quartile concentrations of PFOA and PFOS are presented in the 
main text. Initially, each association was examined considering only PFOA or PFOS as an 
exposure (unadjusted results for linear models only are shown). Age and gender were then 
included as obligatory covariates. The effect of age on antibody titer rise and ratio was 
found to be nonlinear; therefore, age was fitted using a restricted cubic spline function with 
7 knots in the linear regression model. The possible effect of additional a priori confounders 
including smoking status, any previous influenza vaccination (participants were excluded if 
this had occurred in the last 3 months), specific H1N1 vaccination in the previous year, day 
of serum sample collection, coexisting medical conditions and common anti-inflammatory, 
and pain relief medications was also considered. Potential confounders associated with the 
log10-transformed antibody titer rise or antibody titer ratio of that vaccine strain (p < .20) 
were tested in the model and retained if they remained independently associated with the 
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outcome (p < .05). The confounders included in the final linear regression models were age 
(fitted as cubic spline), gender, mobility (as measured by the number of addresses since 
1970 or birth), and a history of previous influenza vaccination.
Multivariable logistic regression models were used to calculate odds ratios to assess the 
effect of PFOA and PFOS on the likelihood of achieving seroconversion or seroprotection 
following vaccination. The odds ratio represents a close approximation of relative risk. A 
priori confounders associated with seroconversion or seroprotection (p < .20) in univariate 
analysis were included in a multivariate regression model and retained if they remained 
independently associated with the outcome (p < .05). In the logistic regression model, age 
was modeled as a categorical variable in 10-year age bands. Only adjusted models are 
presented in the text.
Multivariable logistic regression models were also used to calculate odds ratios to assess the 
effect of serum PFAA levels on the likelihood of influenza and colds in the past year. 
Because the symptoms of influenza are not readily distinguished from other respiratory 
infections (Call et al., 2005), both self-reported colds and influenza were considered in this 
analysis. Ordered multi-variable logistic regression was used to test whether there was a risk 
between increasing frequency of cold and influenza episodes during the year and increased 
PFAA levels. Models for the occurrence of adult influenza were first fitted adjusted for age 
and sex only. The possible effect of other a priori con-founders including smoking status, 
alcohol intake, body mass index, diagnosis of diabetes, and educational level was also 
considered but was not found to significantly affect the final model. All statistical analysis 
was conducted using Stata 12.1 (StataCorp, Texas).
Results
Baseline
A total of 411 adults had a prevaccination antibody titer taken and received the influenza 
vaccination as part of the study (Table 1). The population median log10 serum PFOA 
concentration was 1.50 (IQR: 1.14, 1.95) and PFOS, 0.96 (IQR: 0.76, 1.16), reflecting a 
geometric mean concentration of 33.74 ng/ml (95% confidence interval [CI]: 29.78, 38.22) 
and 8.32 ng/ml (95% CI: 7.65, 9.05), respectively. There was a modest trend of higher 
PFOA and PFOS concentrations among older participants (Table 1). Postvaccination 
serology was available for 403 (98.1%) participants on whom most analysis is based. 
Participants had higher prevaccination antibody GMTs for A/H3N2 than for A/H1N1 and B 
(20.69 [95% CI: 17.87, 23.95], 16.11 [95% CI: 13.90, 18.68], and 8.72 [95% CI: 8.02, 
9.49]), respectively (not shown). Prevaccination GMTs were higher among those who 
reported previous influenza vaccination from last year than those who did not (10.17, 19.81, 
and 31.42 compared with 6.04, 9.83, and 7.60 for B, A/H1N1, and A/H3N2 antigens, 
respectively), and there was a tendency toward greater pre-existing immunity 
(prevaccination titers) among those who reported greater residential mobility (a higher 
number of previous addresses) (Table 1). Following vaccination, there was strong evidence 
of a larger response to A/H1N1 (overall GMT rise 343.08 [95% CI: 296.07, 397.56]) 
compared with A/H3N2 (151.49 [95% CI: 126.19, 181.86]) or B (44.21 [95% CI: 38.58, 
50.66]). Furthermore, the antibody response to A/H1N1 was strongly associated with age, 
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being higher among younger participants (Supplementary Table S1). For Flu B, a higher 
antibody response was seen among men than women (54.47 [95% CI: 44.92, 66.05] and 
35.32 [95% CI: 29.26, 42.64], respectively), and for both A/H1N1 and B, there was strong 
evidence that those who reported previous influenza vaccination had lower antibody 
responses than those who did not (34.91 and 296.68 compared with 74.41 and 467.28 for B 
and H1N1, respectively) (Supplementary Table S1).
Details of prevaccination antibody GMTs by medical comorbidity and medication groups 
can be found in Supplementary Table S2. Participants with a history of asthma had a higher 
prevaccination GMT for H1N1 than those without, reflecting the higher rate of previous A/
H1N1 vaccination reported among those with asthma (65% vs 35.2%, p = .03 [not shown on 
table]). Similarly, those with diabetes reported both higher rates of previous influenza 
vaccination and had a higher prevaccination GMT for A/H3N2 than those without diabetes 
(41.38 [95% CI: 25.37, 67.48] vs 19.16 [95% CI: 16.45, 22.30]).
Vaccine Response
GMT rise—Vaccine response as measured by the GMT rise against each of the 3 vaccine 
components is shown in Table 2 by quartile of PFAA. Individuals in the fourth quartile of 
PFOA exposure had a lower GMT rise in Flu B; however, this trend was less evident for A/
H1N1 and PFOA. For other A/H3N2 and PFOA and for any type with PFOS, there was no 
evident pattern with rise in antibody titers.
Log10-transformed antibody titer rise and ratio—There was a negative association 
between log10-transformed A/H3N2 antibody titer ratio and PFOA when log10-transformed 
PFOA was fitted as a continuous variable in the regression model (adjusted coefficient 
−0.12 [95% CI: −0.25, 0.02, p = .09]) (Table 3). By PFOA quartile, the A/H3N2 antibody 
titer ratio showed a largest reduction in response for the highest quartile of PFOA 
concentrations (adjusted coefficient −0.22 [95% CI: −0.43, −0.01]) (Table 3).
For titer rise, there was no overall trend with exposure, but the second and third quartiles of 
PFOA concentration had lower rises in log10-transformed A/H3N2 antibody titers than those 
in the first quartile (adjusted coefficients −0.28 [95% CI: −0.51, −0.06] for second quartile 
and −0.37 [95% CI: −0.60, 0.13], respectively) (Table 3).
Although unadjusted results suggested a negative association between log10-transformed A/
H1N1 antibody titer rise with quartiles of PFOA concentrations, both PFOA blood 
concentrations and A/H1N1 antibody response are related to age, and this association did 
not persist in the adjusted model (Table 3). The effects on A/H3N2 antibody titers were not 
confounded by age. There was no suggestion from the linear regression analysis of an 
association between influenza B antibody titer rise or ratio and PFOA or PFOS 
concentrations (Table 3).
Seroconversion/seroprotection—Seroconversion for influenza vaccines was defined 
as having a 4-fold increase in antibody titer. Seroprotection was defined as an HI antibody 
titer ≥ 1:40 postvaccination independent of the prevaccine HI titer. Both are used as 
evidence of efficacy to help support the licensing of seasonal inactivated influenza vaccines 
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(FDA, 2007). The proportions of participants who seroconverted following vaccination and 
associations with PFAA are shown in Table 4. Overall, a higher proportion of participants 
seroconverted to H1N1 than H3N2 and B (84.12% [95% CI: 80.54, 87.70] compared with 
64.76% [60.08, 69.45] and 62.03% [57.28, 66.79] for H3N2 and B antigens, respectively). 
As expected, previous influenza vaccination was associated with a decreased likelihood of 
seroconverting to all 3 components of the vaccine (ORs 0.25, 0.13, and 0.31 for B, A/H1N1, 
and A/H3N2, respectively; p < .01 for all) (Supplementary Table S4). Increased age was 
also associated with decreased odds of seroconverting to influenza B (p = .04) and a higher 
proportion of men seroconverted to B than women (68.3% vs 55.6) (Supplementary Table 
S4). There was weak evidence of odds of seroconversion to A/H1N1 increasing with PFOA 
concentration with the odds ratio rising to 2.23 (0.90–5.53) in the fourth quartile, but all 
confidence intervals were wide, and we observed no other associations of note between 
PFOA or PFOS and likelihood of seroconverting to the vaccine components.
The proportions of participants who were seroprotected (HI titer ≥ 40) at their 
postvaccination blood test were 95.5% for A/H1N1, 83.9% for A/H3N2, and 66% for B. 
(Table 5). Unlike B and A/H3N2, the response to A/H1N1 was not strongly associated with 
whether the participant had received a previous influenza vaccination (Supplementary Table 
S5). Participants who reported previous influenza vaccination had a decreased likelihood of 
seroprotection for B (odds ratio [OR]: 0.50 [95% CI: 0.29, 0.84], p = .01), but an increased 
likelihood of seroprotection to A/H3N2 (OR: 2.09 [95% CI: 1.18, 3.69], p = .01) 
(Supplementary Table S5). Increasing age was also strongly associated with decreased 
seroprotection for B and H1N1 (Supplementary Table S5).
After adjustment for age, gender, and past vaccination, there was some evidence of 
seroprotection for decreased likelihood of seroprotection from A/H3N2 in relation to PFOA 
(by PFOA quartile the odds ratios were 0.34 [0.14, 0.83], p = .02, 0.28 [0.11, 0.70], p = .01, 
and 0.39 [0.15, 0.99], p = .05, respectively). Conversely, there was a suggestion of an 
increasing trend of seroprotection for A/H1N1, with an overall OR of 2.34 (0.91–6.07) per 
log unit of PFOA. No other strong associations between seroprotection and PFOA or PFOS 
levels were found.
Self-reported cold and influenza episodes—Data were available on the frequency of 
respiratory infections in the population of the entire follow-up study (n = 755), which 
included those who participated in the vaccination study. One hundred and sixty-three 
(21.6%) adult participants reported an episode of influenza in the 12 months preceding the 
questionnaire, whereas 538 (71.3%) reported a cold in the same time period (Tables 6 and 
7). Age was a major confounder with younger participants who more likely to report colds 
and flu and more likely to have had lower PFAA levels (Table 1). Adjusted models assessed 
either colds or flu, comparing those with and without a reported infection in relation to 
either log PFAA as a continuous variable or quartiles of PFAA concentration. For colds, the 
frequency of reported episodes was also assessed. There was no evidence for any association 
between PFAA concentrations and either self-reported colds or flu (Tables 6 and 7).
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This study offered a unique opportunity to help determine whether PFAA concentrations 
affected the humoral antibody response in humans as determined by HI titers following adult 
seasonal influenza vaccine. The opportunity to determine pre-and postvaccination HI titers 
allowed 4 measures of immune response—the rise, the ratio, seroconversion, and 
seroprotection—to be evaluated in relation to concurrent measured serum concentrations of 
PFOA and PFOS. This design is particularly valuable in the assessment of influenza 
vaccines, which are designed to protect against commonly circulating viruses, and in adults, 
for whom immune function is a product of the recent study vaccine response, prior 
vaccinations, and pre-existing viral exposures. This design allowed assessment of the 
association of circulating levels of PFAA and the humoral immune response following 
immunization to 3 influenza subtypes relative to previous influenza-specific antibody levels 
and also with the attainment of a relative protection antibody threshold. It is important to 
note that HI titers in vaccine studies serve only as a surrogate for protection from influenza 
illness or disease, and the absolute antibody titer that confers protection has not been 
defined.
Age was found to be highly correlated with both pre-existing immunity and vaccine 
response to some but not all of the subtypes examined. The finding of decreasing antibody 
response to influenza vaccination with increasing age and history of influenza vaccination in 
previous years is consistent with a number of studies of influenza vaccine response. Age was 
carefully adjusted for by using a cubic spline term for age in the adjusted linear regression 
models. However, the higher vaccine response to influenza B found among men has not 
been reported elsewhere. This gender difference in the study was isolated to this virus 
serotype and is not consistent with other published studies (Cook, 2008; Engler et al., 2008; 
Klein et al., 2010), suggesting that this may be a chance finding.
The most consistent finding in relation to the 2 exposures considered and the 3 flu strains 
was evidence of a reduced antibody response to A/H3N2 influenza vaccine by higher PFOA 
concentration, refected in the results for titer rise, titer ratio, and seroprotection, though not 
seroconversion. confidence intervals were relatively wide, especially when separated into 
quartile groups, but some results, most notably the reduction in seroprotection, were 
significantly lower in higher serum PFOA concentration quartiles. These results suggest that 
individuals with raised PFOA concentrations have an increased risk of not attaining the 
antibody threshold considered to offer long-term protection from this virus strain. There 
were no other consistent associations, the only other associations coming close to statistical 
significance being increases in immune response in for A/H1N1 in relation to PFOS (titer 
rise) and PFOA (seroconversion and seroprotection, top quartile only).
Previous animal and human studies have suggested PFAAs are associated with a general 
suppression of humoral immune response; however, we only observed strong evidence of 
suppression to the A/H3N2 vaccine component. The differences in the ability of the various 
influenza strains to show a significant effect in relationship to PFOA concentrations may be 
due to differences in their antigenic determinants. Those strains with more conserved 
antigenic determinants (epitopes) would likely have a more significant memory cell 
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response. It is generally thought that memory cell responses are less sensitive to chemical 
immunosuppression than the primary, and thus, response to strains containing more 
conserved antigenic determinants than other strains might be less likely to show an effect or 
at least behave kinetically different in their immune response due to a more significant 
memory cell response. Nonetheless, the lack of consistency between the various endpoints 
increases the plausibility that the results are due to chance.
In addition to age, a number of medical comorbidities and medications were also considered 
as potential contributors to, or confounders of, vaccine response; however, the regression 
models failed to find any evidence of these associations, likely due in part to the low 
prevalence of these factors in this population. A potential limitation in the study was the 
reporting of previous vaccination. Analysis revealed the strong effect of previous influenza 
vaccination on immune response. This information was self-reported by participants using a 
questionnaire. Without validation, this factor has the potential for recall bias, and the 
variation in seasonal influenza vaccine year to year would alter the degree to which previous 
vaccination infers pre-existing immunity against the study vaccine. However, we consider it 
unlikely that any problems with recall of past vaccinations would be associated with PFAA 
category.
The reduced influenza vaccine response observed in this study in adults with elevated PFOA 
concentrations is of note given the findings reported previously in children by Grandjean et 
al. (2012) and Granum et al. (2013) showing similar effects. In addition to the differences in 
the ages of the participants, the most significant difference between our study and theirs was 
in the experimental design. The latter studies collected serum for analysis only prior and not 
following booster immunizations. Boosters for childhood vaccinations are normally 
conducted at least 3 years or more following the initial immunization to stimulate memory 
cell responses. Hence, significant decay of the primary antibody response would have 
occurred as peak IgG levels appear 21 days postimmunization. Swartz et al. (2003) in a 
large study monitoring vaccine titers in children following infant immunization showed that 
the antibody titer decays by > 90% from the primary immunization within 3 years prior to 
booster. Thus, the titers reported from the previous PFAA studies in children represent 
differences detected from residual antibody and not the peak response that we monitored. 
On the other hand, participants in our study had prevaccination titers for all vaccine viruses, 
especially A/H1N1 which would not have been expected following infant immunization. 
This pre-existing immunity may have limited the power of our study to capture differences 
between exposure groups in antibody titer rises.
Our study found no association between PFAA concentration and recent self-reported cold 
or influenza episodes. It is possible that the extent of suppression in the vaccine response 
associated with PFOA exposure is insufficient to change in an individual's risk of infections, 
particularly in a small population. Given the high background rate of respiratory infections, 
with over 70% of adults reported having experienced an episode in the preceding 12 months, 
there is not much scope to detect an increase in infections. Furthermore, self-report 
respiratory infection, particularly influenza, has poor specificity and sensitivity, particularly 
during times of pandemic virus circulation and subsequent heightened public awareness 
(Jutel et al., 2011). During the 2009/2010 influenza season in the United States, the main 
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circulating virus was the 2009 pandemic influenza A (H1N1), and very few other seasonal 
influenza viruses were detected (CDC, 2010). Therefore, if the impact of the A/H3N2 strain 
of influenza specifically was affected by PFOA serum concentrations, it is plausible that 
there was too little of this virus type circulating to detect this association in self-reported 
influenza cases.
In any case, our findings provide evidence that PFOA at serum concentrations between 13.7 
and 90 ng/ml, about 4- to 5-fold above the current levels found in the general U.S. 
population (Kato et al., 2011b), are associated with a reduced HI response to A/H3N2 
influenza virus, a commonly occurring flu virus. We found no evidence of an association 
between self-reported colds or influenza and PFAA concentrations. Furthermore, we saw no 
evidence that PFOS serum concentrations are associated with reduced vaccine responses.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Table 2
GMT Rise Following Vaccination (95% CI) by Quartile of PFOA/PFOS Serum 
Concentration (n = 403)
Influenza Type B Influenza Type A H1N1 Influenza A H3N2
GMT (95% CI) GMT (95% CI) GMT (95% CI)
PFOA and PFOS serum concentrations at time of vaccination
PFOAa
 First quartile 49.46 (38.14, 64.12) 476.23 (360.77, 628.65) 228.86 (161.53, 324.27)
 Second quartile 46.00 (35.28, 59.97) 352.22 (255.33, 485.88) 125.36 (86.01, 182.73)
 Third quartile 43.55 (33.08, 57.33) 306.32 (232.58, 403.44) 104.13 (72.47, 149.64)
 Fourth quartile 20.90 (16.58, 28.24) 274.79 (202.85, 372.23) 183.73 (127.28, 265.23)
PFOSb
 First quartile 42.25 (33.41, 53.42) 342.31 (256.04, 457.65) 137.69 (98.70, 192.09)
 Second quartile 41.48 (30.73, 55.99) 280.44 (197.64, 397.92) 147.27 (99.27, 218.47)
 Third quartile 41.13 (31.65, 53.44) 417.74 (318.99, 547.07) 211.02 (141.24, 315.27)
 Fourth quartile 52.83 (38.92, 71.71) 341.82 (258.03, 452.81) 126.69 (88.85, 180.65)
Note. Bold values represent significant associations. Range of PFAA concentrations within quartiles:
a
PFOA: First quartile: 0.25–13.7 ng/ml; second quartile: 13.8–31.5 ng/ml; third quartile: 31.6–90 ng/ml; fourth quartile: 90.4–2140 ng/ml.
b
PFOS: First quartile: 0.1–5.8 ng/ml; second quartile: 5.9–9.2 ng/ml; third quartile: 9.3–14.5 ng/ml; fourth quartile: 14.7–42.3 ng/ml.
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Table 7
Frequency of Cold Infections in 12 Months Preceding Questionnaire (n = 755)















OR for frequency of colds in last 12 months
 Log10-transformed PFOA/PFOS (continuous) 0.91 (0.70, 1.19) .51 0.89 (0.60, 1.33) .58
 PFOA/PFOS exposure group (categorical)
  First quartile 1 1
  Second quartile 0.93 (0.63, 1.38) 1.56 (1.05, 2.31)
  Third quartile 0.95 (0.63, 1.41) 1.05 (0.70, 1.56)
  Fourth quartile 0.90 (0.60, 1.36) .97 1.10 (0.71, 1.69) .10
a
Note. Adjusted for age (cubic spline) and gender.
b
Likelihood-ratio test.
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